Bcl-2 proteins in development, health, and disease of the hematopoietic system

FEBS Journal

Volumn , Issue , 2016, Pages 2779-2810

  Kollek, Matthias ^a,b   Müller, Alexandra ^a   Egle, Alexander ^c   Erlacher, Miriam ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

^b UNIVERSITY OF FREIBURG   (Germany)

^c PARACELSUS MEDICAL UNIVERSITY   (Austria)

Author keywords

apoptosis; Bcl 2; BH3 only proteins; bone marrow failure; cytopenia; erythropoiesis; hematopoiesis; megakaryopoiesis; myelopoiesis; myeloproliferation

Indexed keywords

ATM PROTEIN; ATR PROTEIN; BIM PROTEIN; CD34 ANTIGEN; CD38 ANTIGEN; CHECKPOINT KINASE 1; CHECKPOINT KINASE 2; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 3; LEUKOSIALIN; OBATOCLAX; PROTEIN BAK; PROTEIN BAX; PROTEIN BCL 2; PROTEIN BCL XL; PROTEIN MCL 1; PROTEIN MDM2; PROTEIN P53; PUMA PROTEIN; STAT5 PROTEIN; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 2; TRANSCRIPTION FACTOR RUNX1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED DEATH DOMAIN PROTEIN; UNINDEXED DRUG; VASCULOTROPIN; VENETOCLAX;

APOPTOSIS; ARTICLE; BONE MARROW; CANCER THERAPY; CELL DEATH; CELL FUNCTION; CELL LINEAGE; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; DNA DAMAGE; DNA END JOINING REPAIR; DOWN REGULATION; ERYTHROPOIESIS; GENOTOXICITY; HEMATOLOGIC DISEASE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC SYSTEM; HUMAN; INFLAMMATION; LEUKEMIA; LYMPHOCYTE; LYMPHOMA; MEGAKARYOCYTE; MEMBRANE PERMEABILITY; MYELOPOIESIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEPLETION; PROTEIN FUNCTION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; THROMBOCYTE;

EID: 84982980919     PISSN: 1742464X     EISSN: 17424658     Source Type: Journal    
DOI: 10.1111/febs.13683     Document Type: Article

References (260)

1. Ogawa M (1993) Differentiation and proliferation of hematopoietic stem cells. Blood 81, 2844–2853.
2. Doulatov S, Notta F, Laurenti E & Dick JE (2012) Hematopoiesis: a human perspective. Cell Stem Cell 10, 120–136.
3. Nagata S (1997) Apoptosis by death factor. Cell 88, 355–365.
4. Czabotar PE, Lessene G, Strasser A & Adams JM (2014) Control of apoptosis by the BCL-2 protein family: implications for physiology and therapy. Nat Rev Mol Cell Biol 15, 49–63.
5. Zou H, Henzel WJ, Liu X, Lutschg A & Wang X (1997) Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90, 405–413.
6. Babovic S & Eaves CJ (2014) Hierarchical organization of fetal and adult hematopoietic stem cells. Exp Cell Res 329, 185–191.
7. Baron MH, Isern J & Fraser ST (2012) The embryonic origins of erythropoiesis in mammals. Blood 119, 4828–4837.
8. Orelio C, Harvey KN, Miles C, Oostendorp RA, van der Horn K & Dzierzak E (2004) The role of apoptosis in the development of AGM hematopoietic stem cells revealed by Bcl-2 overexpression. Blood 103, 4084–4092.
9. Nakayama K, Nakayama K, Negishi I, Kuida K, Shinkai Y, Louie MC, Fields LE, Lucas PJ, Stewart V, Alt FW et al. (1993) Disappearance of the lymphoid system in Bcl-2 homozygous mutant chimeric mice. Science (New York, NY) 261, 1584–1588.
10. Veis DJ, Sorenson CM, Shutter JR & Korsmeyer SJ (1993) Bcl-2-deficient mice demonstrate fulminant lymphoid apoptosis, polycystic kidneys, and hypopigmented hair. Cell 75, 229–240.
11. Akhtar RS, Klocke BJ, Strasser A & Roth KA (2008) Loss of BH3-only protein Bim inhibits apoptosis of hemopoietic cells in the fetal liver and male germ cells but not neuronal cells in bcl-x-deficient mice. J Histochem Cytochem 56, 921–927.
12. Motoyama N, Wang F, Roth KA, Sawa H, Nakayama K, Nakayama K, Negishi I, Senju S, Zhang Q, Fujii S et al. (1995) Massive cell death of immature hematopoietic cells and neurons in Bcl-x-deficient mice. Science (New York, NY) 267, 1506–1510.
13. Motoyama N, Kimura T, Takahashi T, Watanabe T & Nakano T (1999) bcl-x prevents apoptotic cell death of both primitive and definitive erythrocytes at the end of maturation. J Exp Med 189, 1691–1698.
14. Zaidi AU, D'Sa-Eipper C, Brenner J, Kuida K, Zheng TS, Flavell RA, Rakic P & Roth KA (2001) Bcl-X(L)-caspase-9 interactions in the developing nervous system: evidence for multiple death pathways. J Neurosci 21, 169–175.
15. Bouillet P, Metcalf D, Huang DC, Tarlinton DM, Kay TW, Kontgen F, Adams JM & Strasser A (1999) Proapoptotic Bcl-2 relative Bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity. Science (New York, NY) 286, 1735–1738.
16. Rinkenberger JL, Horning S, Klocke B, Roth K & Korsmeyer SJ (2000) Mcl-1 deficiency results in peri-implantation embryonic lethality. Genes Dev 14, 23–27.
17. Sano M, Umezawa A, Suzuki A, Shimoda K, Fukuma M & Hata J (2000) Involvement of EAT/mcl-1, an anti-apoptotic bcl-2-related gene, in murine embryogenesis and human development. Exp Cell Res 259, 127–139.
18. Chen MJ, Yokomizo T, Zeigler BM, Dzierzak E & Speck NA (2009) Runx1 is required for the endothelial to haematopoietic cell transition but not thereafter. Nature 457, 887–891.
19. de Pater E, Kaimakis P, Vink CS, Yokomizo T, Yamada-Inagawa T, van der Linden R, Kartalaei PS, Camper SA, Speck N & Dzierzak E (2013) Gata2 is required for HSC generation and survival. J Exp Med 210, 2843–2850.
20. Souroullas GP, Salmon JM, Sablitzky F, Curtis DJ & Goodell MA (2009) Adult hematopoietic stem and progenitor cells require either Lyl1 or Scl for survival. Cell Stem Cell 4, 180–186.
21. Rodrigues NP, Janzen V, Forkert R, Dombkowski DM, Boyd AS, Orkin SH, Enver T, Vyas P & Scadden DT (2005) Haploinsufficiency of GATA-2 perturbs adult hematopoietic stem-cell homeostasis. Blood 106, 477–484.
22. Till JE & Mc CE (1961) A direct measurement of the radiation sensitivity of normal mouse bone marrow cells. Radiat Res 14, 213–222.
23. Orford KW & Scadden DT (2008) Deconstructing stem cell self-renewal: genetic insights into cell-cycle regulation. Nat Rev Genet 9, 115–128.
24. Li L & Bhatia R (2011) Stem cell quiescence. Clin Cancer Res 17, 4936–4941.
25. Eliasson P & Jonsson JI (2010) The hematopoietic stem cell niche: low in oxygen but a nice place to be. J Cell Physiol 222, 17–22.
26. Wang MW, Consoli U, Lane CM, Durett A, Lauppe MJ, Champlin R, Andreeff M & Deisseroth AB (1998) Rescue from apoptosis in early (CD34-selected) versus late (non-CD34-selected) human hematopoietic cells by very late antigen 4- and vascular cell adhesion molecule (VCAM) 1-dependent adhesion to bone marrow stromal cells. Cell Growth Differ 9, 105–112.
27. Varnum-Finney B, Xu L, Brashem-Stein C, Nourigat C, Flowers D, Bakkour S, Pear WS & Bernstein ID (2000) Pluripotent, cytokine-dependent, hematopoietic stem cells are immortalized by constitutive Notch1 signaling. Nat Med 6, 1278–1281.
28. Butler JM, Nolan DJ, Vertes EL, Varnum-Finney B, Kobayashi H, Hooper AT, Seandel M, Shido K, White IA, Kobayashi M et al. (2010) Endothelial cells are essential for the self-renewal and repopulation of Notch-dependent hematopoietic stem cells. Cell Stem Cell 6, 251–264.
29. Qian H, Buza-Vidas N, Hyland CD, Jensen CT, Antonchuk J, Mansson R, Thoren LA, Ekblom M, Alexander WS & Jacobsen SE (2007) Critical role of thrombopoietin in maintaining adult quiescent hematopoietic stem cells. Cell Stem Cell 1, 671–684.
30. Gerber HP, Malik AK, Solar GP, Sherman D, Liang XH, Meng G, Hong K, Marsters JC & Ferrara N (2002) VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism. Nature 417, 954–958.
31. Murray LJ, Young JC, Osborne LJ, Luens KM, Scollay R & Hill BL (1999) Thrombopoietin, flt3, and kit ligands together suppress apoptosis of human mobilized CD34+ cells and recruit primitive CD34+ Thy-1+ cells into rapid division. Exp Hematol 27, 1019–1028.
32. Suzuki N, Yamazaki S, Ema H, Yamaguchi T, Nakauchi H & Takaki S (2012) Homeostasis of hematopoietic stem cells regulated by the myeloproliferative disease associated-gene product Lnk/Sh2b3 via Bcl-xL. Exp Hematol 40, 166–74.e3.
33. Nunez G, London L, Hockenbery D, Alexander M, McKearn JP & Korsmeyer SJ (1990) Deregulated Bcl-2 gene expression selectively prolongs survival of growth factor-deprived hemopoietic cell lines. J Immunol (Baltimore, Md.: 1950) 144, 3602–3610.
34. Domen J & Weissman IL (2003) Hematopoietic stem cells and other hematopoietic cells show broad resistance to chemotherapeutic agents in vivo when overexpressing bcl-2. Exp Hematol 31, 631–639.
35. Labi V, Bertele D, Woess C, Tischner D, Bock FJ, Schwemmers S, Pahl HL, Geley S, Kunze M, Niemeyer CM et al. (2013) Haematopoietic stem cell survival and transplantation efficacy is limited by the BH3-only proteins Bim and Bmf. EMBO Mol Med 5, 122–136.
36. Ogilvy S, Metcalf D, Print CG, Bath ML, Harris AW & Adams JM (1999) Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. Proc Natl Acad Sci USA 96, 14943–14948.
37. Domen J, Cheshier SH & Weissman IL (2000) The role of apoptosis in the regulation of hematopoietic stem cells: overexpression of Bcl-2 increases both their number and repopulation potential. J Exp Med 191, 253–264.
38. Opferman JT, Iwasaki H, Ong CC, Suh H, Mizuno S, Akashi K & Korsmeyer SJ (2005) Obligate role of anti-apoptotic MCL-1 in the survival of hematopoietic stem cells. Science (New York, NY) 307, 1101–1104.
39. Delbridge AR, Opferman JT, Grabow S & Strasser A (2015) Antagonism between MCL-1 and PUMA governs stem/progenitor cell survival during hematopoietic recovery from stress. Blood 125, 3273–3280.
40. Chang J, Wang Y, Shao L, Laberge RM, Demaria M, Campisi J, Janakiraman K, Sharpless NE, Ding S, Feng W et al. (2016) Clearance of senescent cells by ABT263 rejuvenates aged hematopoietic stem cells in mice. Nat Med 22, 78–83.
41. Flach J, Bakker ST, Mohrin M, Conroy PC, Pietras EM, Reynaud D, Alvarez S, Diolaiti ME, Ugarte F, Forsberg EC et al. (2014) Replication stress is a potent driver of functional decline in ageing haematopoietic stem cells. Nature 512, 198–202.
42. Campbell CJ, Lee JB, Levadoux-Martin M, Wynder T, Xenocostas A, Leber B & Bhatia M (2010) The human stem cell hierarchy is defined by a functional dependence on Mcl-1 for self-renewal capacity. Blood 116, 1433–1442.
43. Vo TT, Ryan J, Carrasco R, Neuberg D, Rossi DJ, Stone RM, Deangelo DJ, Frattini MG & Letai A (2012) Relative mitochondrial priming of myeloblasts and normal HSCs determines chemotherapeutic success in AML. Cell 151, 344–355.
44. Park JR, Bernstein ID & Hockenbery DM (1995) Primitive human hematopoietic precursors express Bcl-x but not Bcl-2. Blood 86, 868–876.
45. Peters R, Leyvraz S & Perey L (1998) Apoptotic regulation in primitive hematopoietic precursors. Blood 92, 2041–2052.
46. Italiano JE Jr, Lecine P, Shivdasani RA & Hartwig JH (1999) Blood platelets are assembled principally at the ends of proplatelet processes produced by differentiated megakaryocytes. J Cell Biol 147, 1299–1312.
47. Svoboda O & Bartunek P (2015) Origins of the vertebrate erythro/megakaryocytic system. Biomed Res Int 2015, 632171.
48. Debrincat MA, Josefsson EC, James C, Henley KJ, Ellis S, Lebois M, Betterman KL, Lane RM, Rogers KL, White MJ et al. (2012) Mcl-1 and Bcl-x(L) coordinately regulate megakaryocyte survival. Blood 119, 5850–5858.
49. De Botton S, Sabri S, Daugas E, Zermati Y, Guidotti JE, Hermine O, Kroemer G, Vainchenker W & Debili N (2002) Platelet formation is the consequence of caspase activation within megakaryocytes. Blood 100, 1310–1317.
50. Kaluzhny Y & Ravid K (2004) Role of apoptotic processes in platelet biogenesis. Acta Haematol 111, 67–77.
51. Josefsson EC, Burnett DL, Lebois M, Debrincat MA, White MJ, Henley KJ, Lane RM, Moujalled D, Preston SP, O'Reilly LA et al. (2014) Platelet production proceeds independently of the intrinsic and extrinsic apoptosis pathways. Nat Commun 5, 3455.
52. White MJ, Schoenwaelder SM, Josefsson EC, Jarman KE, Henley KJ, James C, Debrincat MA, Jackson SP, Huang DC & Kile BT (2012) Caspase-9 mediates the apoptotic death of megakaryocytes and platelets, but is dispensable for their generation and function. Blood 119, 4283–4290.
53. Josefsson EC, James C, Henley KJ, Debrincat MA, Rogers KL, Dowling MR, White MJ, Kruse EA, Lane RM, Ellis S et al. (2011) Megakaryocytes possess a functional intrinsic apoptosis pathway that must be restrained to survive and produce platelets. J Exp Med 208, 2017–2031.
54. Kodama T, Hikita H, Kawaguchi T, Shigekawa M, Shimizu S, Hayashi Y, Li W, Miyagi T, Hosui A, Tatsumi T et al. (2012) Mcl-1 and Bcl-xL regulate Bak/Bax-dependent apoptosis of the megakaryocytic lineage at multistages. Cell Death Differ 19, 1856–1869.
55. Debrincat MA, Pleines I, Lebois M, Lane RM, Holmes ML, Corbin J, Vandenberg CJ, Alexander WS, Ng AP, Strasser A et al. (2015) BCL-2 is dispensable for thrombopoiesis and platelet survival. Cell Death Dis 6, e1721.
56. Mason KD, Carpinelli MR, Fletcher JI, Collinge JE, Hilton AA, Ellis S, Kelly PN, Ekert PG, Metcalf D, Roberts AW et al. (2007) Programmed anuclear cell death delimits platelet life span. Cell 128, 1173–1186.
57. Souers AJ, Leverson JD, Boghaert ER, Ackler SL, Catron ND, Chen J, Dayton BD, Ding H, Enschede SH, Fairbrother WJ et al. (2013) ABT-199, a potent and selective BCL-2 inhibitor, achieves antitumor activity while sparing platelets. Nat Med 19, 202–208.
58. Vandenberg C, Josefsson E, Campbell K, James C, Lawlor K, Kile B & Cory S (2014) Loss of Bak enhances lymphocytosis but does not ameliorate thrombocytopaenia in BCL-2 transgenic mice. Cell Death Differ 21, 676–684.
59. Patel SR, Hartwig JH & Italiano JE Jr (2005) The biogenesis of platelets from megakaryocyte proplatelets. J Clin Investig 115, 3348–3354.
60. Kozuma Y, Yuki S, Ninomiya H, Nagasawa T & Kojima H (2009) Caspase activation is involved in early megakaryocyte differentiation but not in platelet production from megakaryocytes. Leukemia 23, 1080–1086.
61. Sanz C, Benet I, Richard C, Badia B, Andreu EJ, Prosper F & Fernandez-Luna JL (2001) Antiapoptotic protein Bcl-x(L) is up-regulated during megakaryocytic differentiation of CD34(+) progenitors but is absent from senescent megakaryocytes. Exp Hematol 29, 728–735.
62. Mortensen M, Ferguson DJ, Edelmann M, Kessler B, Morten KJ, Komatsu M & Simon AK (2010) Loss of autophagy in erythroid cells leads to defective removal of mitochondria and severe anemia in vivo. Proc Natl Acad Sci USA 107, 832–837.
63. Foller M, Huber SM & Lang F (2008) Erythrocyte programmed cell death. IUBMB Life 60, 661–668.
64. Magnani M, Rossi L, Stocchi V, Cucchiarini L, Piacentini G & Fornaini G (1988) Effect of age on some properties of mice erythrocytes. Mech Ageing Dev 42, 37–47.
65. Silva M, Grillot D, Benito A, Richard C, Nunez G & Fernandez-Luna JL (1996) Erythropoietin can promote erythroid progenitor survival by repressing apoptosis through Bcl-XL and Bcl-2. Blood 88, 1576–1582.
66. Abutin RM, Chen J, Lung TK, Lloyd JA, Sawyer ST & Harada H (2009) Erythropoietin-induced phosphorylation/degradation of BIM contributes to survival of erythroid cells. Exp Hematol 37, 151–158.
67. Koulnis M, Porpiglia E, Porpiglia PA, Liu Y, Hallstrom K, Hidalgo D & Socolovsky M (2012) Contrasting dynamic responses in vivo of the Bcl-xL and Bim erythropoietic survival pathways. Blood 119, 1228–1239.
68. Gregoli PA & Bondurant MC (1997) The roles of Bcl-X(L) and apopain in the control of erythropoiesis by erythropoietin. Blood 90, 630–640.
69. Dolznig H, Habermann B, Stangl K, Deiner EM, Moriggl R, Beug H & Mullner EW (2002) Apoptosis protection by the Epo target Bcl-X(L) allows factor-independent differentiation of primary erythroblasts. Curr Biol 12, 1076–1085.
70. Wagner KU, Claudio E, Rucker EB III, Riedlinger G, Broussard C, Schwartzberg PL, Siebenlist U & Hennighausen L (2000) Conditional deletion of the Bcl-x gene from erythroid cells results in hemolytic anemia and profound splenomegaly. Development (Cambridge, England) 127, 4949–4958.
71. Wensveen FM, Geest CR, Libregts SF, Derks IA, Ekert PG, Labi V, Villunger A, Nolte MA & Eldering E (2013) BH3-only protein Noxa contributes to apoptotic control of stress-erythropoiesis. Apoptosis 18, 1306–1318.
72. Chen G, Cizeau J, Vande Velde C, Park JH, Bozek G, Bolton J, Shi L, Dubik D & Greenberg A (1999) Nix and Nip3 form a subfamily of pro-apoptotic mitochondrial proteins. J Biol Chem 274, 7–10.
73. Imazu T, Shimizu S, Tagami S, Matsushima M, Nakamura Y, Miki T, Okuyama A & Tsujimoto Y (1999) Bcl-2/E1B 19 kDa-interacting protein 3-like protein (Bnip3L) interacts with bcl-2/Bcl-xL and induces apoptosis by altering mitochondrial membrane permeability. Oncogene 18, 4523–4529.
74. Aerbajinai W, Giattina M, Lee YT, Raffeld M & Miller JL (2003) The proapoptotic factor Nix is coexpressed with Bcl-xL during terminal erythroid differentiation. Blood 102, 712–717.
75. Diwan A, Koesters AG, Odley AM, Pushkaran S, Baines CP, Spike BT, Daria D, Jegga AG, Geiger H, Aronow BJ et al. (2007) Unrestrained erythroblast development in Nix-/- mice reveals a mechanism for apoptotic modulation of erythropoiesis. Proc Natl Acad Sci USA 104, 6794–6799.
76. Sandoval H, Thiagarajan P, Dasgupta SK, Schumacher A, Prchal JT, Chen M & Wang J (2008) Essential role for Nix in autophagic maturation of erythroid cells. Nature 454, 232–235.
77. Novak I, Kirkin V, McEwan DG, Zhang J, Wild P, Rozenknop A, Rogov V, Lohr F, Popovic D, Occhipinti A et al. (2010) Nix is a selective autophagy receptor for mitochondrial clearance. EMBO Rep 11, 45–51.
78. Josefsen D, Myklebust JH, Lomo J, Sioud M, Blomhoff HK & Smeland EB (2000) Differential expression of bcl-2 homologs in human CD34(+) hematopoietic progenitor cells induced to differentiate into erythroid or granulocytic cells. Stem Cells (Dayton, Ohio) 18, 261–272.
79. Erlacher M, Labi V, Manzl C, Bock G, Tzankov A, Hacker G, Michalak E, Strasser A & Villunger A (2006) Puma cooperates with Bim, the rate-limiting BH3-only protein in cell death during lymphocyte development, in apoptosis induction. J Exp Med 203, 2939–2951.
80. Dzhagalov I, St John A & He YW (2007) The antiapoptotic protein Mcl-1 is essential for the survival of neutrophils but not macrophages. Blood 109, 1620–1626.
81. Steimer DA, Boyd K, Takeuchi O, Fisher JK, Zambetti GP & Opferman JT (2009) Selective roles for antiapoptotic MCL-1 during granulocyte development and macrophage effector function. Blood 113, 2805–2815.
82. Kirschnek S, Ying S, Fischer SF, Hacker H, Villunger A, Hochrein H & Hacker G (2005) Phagocytosis-induced apoptosis in macrophages is mediated by up-regulation and activation of the Bcl-2 homology domain 3-only protein Bim. J Immunology (Baltimore, Md.: 1950) 174, 671–679.
83. Shearn AI, Deswaerte V, Gautier EL, Saint-Charles F, Pirault J, Bouchareychas L, Rucker EB III, Beliard S, Chapman J, Jessup W et al. (2012) Bcl-x inactivation in macrophages accelerates progression of advanced atherosclerotic lesions in Apoe(-/-) mice. Arterioscler Thromb Vasc Biol 32, 1142–1149.
84. Thorp E, Li Y, Bao L, Yao PM, Kuriakose G, Rong J, Fisher EA & Tabas I (2009) Brief report: increased apoptosis in advanced atherosclerotic lesions of Apoe-/- mice lacking macrophage Bcl-2. Arterioscler Thromb Vasc Biol 29, 169–172.
85. Orlofsky A, Berger MS & Prystowsky MB (1991) Novel expression pattern of a new member of the MIP-1 family of cytokine-like genes. Cell Regul 2, 403–412.
86. Lin EY, Orlofsky A, Berger MS & Prystowsky MB (1993) Characterization of A1, a novel hemopoietic-specific early-response gene with sequence similarity to bcl-2. J Immunol (Baltimore, Md: 1950) 151, 1979–1988.
87. Simpson LA, Burwell EA, Thompson KA, Shahnaz S, Chen AR & Loeb DM (2006) The antiapoptotic gene A1/BFL1 is a WT1 target gene that mediates granulocytic differentiation and resistance to chemotherapy. Blood 107, 4695–4702.
88. Ottina E, Grespi F, Tischner D, Soratroi C, Geley S, Ploner A, Reichardt HM, Villunger A & Herold MJ (2012) Targeting antiapoptotic A1/Bfl-1 by in vivo RNAi reveals multiple roles in leukocyte development in mice. Blood 119, 6032–6042.
89. Kirschnek S, Vier J, Gautam S, Frankenberg T, Rangelova S, Eitz-Ferrer P, Grespi F, Ottina E, Villunger A, Hacker H et al. (2011) Molecular analysis of neutrophil spontaneous apoptosis reveals a strong role for the pro-apoptotic BH3-only protein Noxa. Cell Death Differ 18, 1805–1814.
90. Wang GG, Calvo KR, Pasillas MP, Sykes DB, Hacker H & Kamps MP (2006) Quantitative production of macrophages or neutrophils ex vivo using conditional Hoxb8. Nat Methods 3, 287–293.
91. Sanz C, Benito A, Silva M, Albella B, Richard C, Segovia JC, Insunza A, Bueren JA & Fernandez-Luna JL (1997) The expression of Bcl-x is downregulated during differentiation of human hematopoietic progenitor cells along the granulocyte but not the monocyte/macrophage lineage. Blood 89, 3199–3204.
92. Busca A, Saxena M, Iqbal S, Angel J & Kumar A (2014) PI3K/Akt regulates survival during differentiation of human macrophages by maintaining NF-kappaB-dependent expression of antiapoptotic Bcl-xL. J Leukoc Biol 96, 1011–1022.
93. Liu H, Perlman H, Pagliari LJ & Pope RM (2001) Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages. Role of Mcl-1, independent of nuclear factor (NF)-kappaB, Bad, or caspase activation. J Exp Med 194, 113–126.
94. Busca A, Saxena M & Kumar A (2012) Critical role for antiapoptotic Bcl-xL and Mcl-1 in human macrophage survival and cellular IAP1/2 (cIAP1/2) in resistance to HIV-Vpr-induced apoptosis. J Biol Chem 287, 15118–15133.
95. Opferman JT, Letai A, Beard C, Sorcinelli MD, Ong CC & Korsmeyer SJ (2003) Development and maintenance of B and T lymphocytes requires antiapoptotic MCL-1. Nature 426, 671–676.
96. Ma A, Pena JC, Chang B, Margosian E, Davidson L, Alt FW & Thompson CB (1995) Bclx regulates the survival of double-positive thymocytes. Proc Natl Acad Sci USA 92, 4763–4767.
97. Ryan JA, Brunelle JK & Letai A (2010) Heightened mitochondrial priming is the basis for apoptotic hypersensitivity of CD4+ CD8+ thymocytes. Proc Natl Acad Sci USA 107, 12895–12900.
98. Dzhagalov I, Dunkle A & He YW (2008) The anti-apoptotic Bcl-2 family member Mcl-1 promotes T lymphocyte survival at multiple stages. J Immunol (Baltimore Md.: 1950) 181, 521–528.
99. Vikstrom I, Carotta S, Luthje K, Peperzak V, Jost PJ, Glaser S, Busslinger M, Bouillet P, Strasser A, Nutt SL et al. (2010) Mcl-1 is essential for germinal center formation and B cell memory. Science (New York NY) 330, 1095–1099.
100. Bouillet P, Cory S, Zhang LC, Strasser A & Adams JM (2001) Degenerative disorders caused by Bcl-2 deficiency prevented by loss of its BH3-only antagonist Bim. Dev Cell 1, 645–653.
101. Gray DH, Kupresanin F, Berzins SP, Herold MJ, O'Reilly LA, Bouillet P & Strasser A (2012) The BH3-only proteins Bim and Puma cooperate to impose deletional tolerance of organ-specific antigens. Immunity 37, 451–462.
102. Labi V, Woess C, Tuzlak S, Erlacher M, Bouillet P, Strasser A, Tzankov A & Villunger A (2014) Deregulated cell death and lymphocyte homeostasis cause premature lethality in mice lacking the BH3-only proteins Bim and Bmf. Blood 123, 2652–2662.
103. Bouillet P, Purton JF, Godfrey DI, Zhang LC, Coultas L, Puthalakath H, Pellegrini M, Cory S, Adams JM & Strasser A (2002) BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 415, 922–926.
104. You H, Pellegrini M, Tsuchihara K, Yamamoto K, Hacker G, Erlacher M, Villunger A & Mak TW (2006) FOXO3a-dependent regulation of Puma in response to cytokine/growth factor withdrawal. J Exp Med 203, 1657–1663.
105. Cohen PL & Eisenberg RA (1991) Lpr and gld: single gene models of systemic autoimmunity and lymphoproliferative disease. Annu Rev Immunol 9, 243–269.
106. Strasser A, Harris AW, Huang DC, Krammer PH & Cory S (1995) Bcl-2 and Fas/APO-1 regulate distinct pathways to lymphocyte apoptosis. EMBO J 14, 6136–6147.
107. Hughes PD, Belz GT, Fortner KA, Budd RC, Strasser A & Bouillet P (2008) Apoptosis regulators Fas and Bim cooperate in shutdown of chronic immune responses and prevention of autoimmunity. Immunity 28, 197–205.
108. Marsden VS & Strasser A (2003) Control of apoptosis in the immune system: Bcl-2, BH3-only proteins and more. Annu Rev Immunol 21, 71–105.
109. Strasser A (2005) The role of BH3-only proteins in the immune system. Nat Rev Immunol 5, 189–200.
110. Opferman JT (2008) Apoptosis in the development of the immune system. Cell Death Differ 15, 234–242.
111. Mirantes C, Passegue E & Pietras EM (2014) Pro-inflammatory cytokines: emerging players regulating HSC function in normal and diseased hematopoiesis. Exp Cell Res 329, 248–254.
112. Essers MA, Offner S, Blanco-Bose WE, Waibler Z, Kalinke U, Duchosal MA & Trumpp A (2009) IFNalpha activates dormant haematopoietic stem cells in vivo. Nature 458, 904–908.
113. Feng CG, Weksberg DC, Taylor GA, Sher A & Goodell MA (2008) The p47 GTPase Lrg-47 (Irgm1) links host defense and hematopoietic stem cell proliferation. Cell Stem Cell 2, 83–89.
114. Santiago HC, Feng CG, Bafica A, Roffe E, Arantes RM, Cheever A, Taylor G, Vieira LQ, Aliberti J, Gazzinelli RT et al. (2005) Mice deficient in LRG-47 display enhanced susceptibility to Trypanosoma cruzi infection associated with defective hemopoiesis and intracellular control of parasite growth. J Immunol (Baltimore Md.: 1950) 175, 8165–8172.
115. Hartner JC, Walkley CR, Lu J & Orkin SH (2009) ADAR1 is essential for the maintenance of hematopoiesis and suppression of interferon signaling. Nat Immunol 10, 109–115.
116. Sato T, Onai N, Yoshihara H, Arai F, Suda T & Ohteki T (2009) Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med 15, 696–700.
117. Pietras EM, Lakshminarasimhan R, Techner JM, Fong S, Flach J, Binnewies M & Passegue E (2014) Re-entry into quiescence protects hematopoietic stem cells from the killing effect of chronic exposure to type I interferons. J Exp Med 211, 245–262.
118. Florido M, Pearl JE, Solache A, Borges M, Haynes L, Cooper AM & Appelberg R (2005) Gamma interferon-induced T-cell loss in virulent Mycobacterium avium infection. Infect Immun 73, 3577–3586.
119. Chen J, Feng X, Desierto MJ, Keyvanfar K & Young NS (2015) IFN-gamma-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure. Blood 126, 2621–2631.
120. Masters SL, Gerlic M, Metcalf D, Preston S, Pellegrini M, O'Donnell JA, McArthur K, Baldwin TM, Chevrier S, Nowell CJ et al. (2012) NLRP1 inflammasome activation induces pyroptosis of hematopoietic progenitor cells. Immunity 37, 1009–1023.
121. Rickard JA, O'Donnell JA, Evans JM, Lalaoui N, Poh AR, Rogers T, Vince JE, Lawlor KE, Ninnis RL, Anderton H et al. (2014) RIPK1 regulates RIPK3-MLKL-driven systemic inflammation and emergency hematopoiesis. Cell 157, 1175–1188.
122. Rossi DJ, Bryder D, Seita J, Nussenzweig A, Hoeijmakers J & Weissman IL (2007) Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age. Nature 447, 725–729.
123. Zhou BB & Elledge SJ (2000) The DNA damage response: putting checkpoints in perspective. Nature 408, 433–439.
124. Miyashita T, Krajewski S, Krajewska M, Wang HG, Lin HK, Liebermann DA, Hoffman B & Reed JC (1994) Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9, 1799–1805.
125. Oda E, Ohki R, Murasawa H, Nemoto J, Shibue T, Yamashita T, Tokino T, Taniguchi T & Tanaka N (2000) Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Science (New York, NY) 288, 1053–1058.
126. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ & El-Deiry WS (2002) BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol 4, 842–849.
127. Miyashita T, Harigai M, Hanada M & Reed JC (1994) Identification of a p53-dependent negative response element in the bcl-2 gene. Cancer Res 54, 3131–3135.
128. Villunger A, Michalak EM, Coultas L, Mullauer F, Bock G, Ausserlechner MJ, Adams JM & Strasser A (2003) p53- and drug-induced apoptotic responses mediated by BH3-only proteins puma and noxa. Science (New York, NY) 302, 1036–1038.
129. Erlacher M, Michalak EM, Kelly PN, Labi V, Niederegger H, Coultas L, Adams JM, Strasser A & Villunger A (2005) BH3-only proteins Puma and Bim are rate-limiting for gamma-radiation- and glucocorticoid-induced apoptosis of lymphoid cells in vivo. Blood 106, 4131–4138.
130. Schuler M, Maurer U, Goldstein JC, Breitenbucher F, Hoffarth S, Waterhouse NJ & Green DR (2003) p53 triggers apoptosis in oncogene-expressing fibroblasts by the induction of Noxa and mitochondrial Bax translocation. Cell Death Differ 10, 451–460.
131. Fridman JS & Lowe SW (2003) Control of apoptosis by p53. Oncogene 22, 9030–9040.
132. Zinkel SS, Hurov KE, Ong C, Abtahi FM, Gross A & Korsmeyer SJ (2005) A role for proapoptotic BID in the DNA-damage response. Cell 122, 579–591.
133. Kamer I, Sarig R, Zaltsman Y, Niv H, Oberkovitz G, Regev L, Haimovich G, Lerenthal Y, Marcellus RC & Gross A (2005) Proapoptotic BID is an ATM effector in the DNA-damage response. Cell 122, 593–603.
134. Maryanovich M, Oberkovitz G, Niv H, Vorobiyov L, Zaltsman Y, Brenner O, Lapidot T, Jung S & Gross A (2012) The ATM-BID pathway regulates quiescence and survival of haematopoietic stem cells. Nat Cell Biol 14, 535–541.
135. Kaufmann T, Tai L, Ekert PG, Huang DC, Norris F, Lindemann RK, Johnstone RW, Dixit VM & Strasser A (2007) The BH3-only protein bid is dispensable for DNA damage-and replicative stress-induced apoptosis or cell-cycle arrest. Cell 129, 423–433.
136. Labi V, Erlacher M, Krumschnabel G, Manzl C, Tzankov A, Pinon J, Egle A & Villunger A (2010) Apoptosis of leukocytes triggered by acute DNA damage promotes lymphoma formation. Genes Dev 24, 1602–1607.
137. Michalak EM, Vandenberg CJ, Delbridge AR, Wu L, Scott CL, Adams JM & Strasser A (2010) Apoptosis-promoted tumorigenesis: gamma-irradiation-induced thymic lymphomagenesis requires Puma-driven leukocyte death. Genes Dev 24, 1608–1613.
138. Mohrin M, Bourke E, Alexander D, Warr MR, Barry-Holson K, Le Beau MM, Morrison CG & Passegue E (2010) Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. Cell Stem Cell 7, 174–185.
139. Domen J, Gandy KL & Weissman IL (1998) Systemic overexpression of BCL-2 in the hematopoietic system protects transgenic mice from the consequences of lethal irradiation. Blood 91, 2272–2282.
140. Milyavsky M, Gan OI, Trottier M, Komosa M, Tabach O, Notta F, Lechman E, Hermans KG, Eppert K, Konovalova Z et al. (2010) A distinctive DNA damage response in human hematopoietic stem cells reveals an apoptosis-independent role for p53 in self-renewal. Cell Stem Cell 7, 186–197.
141. Labi V & Erlacher M (2015) How cell death shapes cancer. Cell Death Dis 6, e1675.
142. Lotem J & Sachs L (1993) Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82, 1092–1096.
143. Liu Y, Elf SE, Miyata Y, Sashida G, Liu Y, Huang G, Di Giandomenico S, Lee JM, Deblasio A, Menendez S et al. (2009) p53 regulates hematopoietic stem cell quiescence. Cell Stem Cell 4, 37–48.
144. Asai T, Liu Y, Di Giandomenico S, Bae N, Ndiaye-Lobry D, Deblasio A, Menendez S, Antipin Y, Reva B, Wevrick R et al. (2012) Necdin, a p53 target gene, regulates the quiescence and response to genotoxic stress of hematopoietic stem/progenitor cells. Blood 120, 1601–1612.
145. Chen J, Ellison FM, Keyvanfar K, Omokaro SO, Desierto MJ, Eckhaus MA & Young NS (2008) Enrichment of hematopoietic stem cells with SLAM and LSK markers for the detection of hematopoietic stem cell function in normal and Trp53 null mice. Exp Hematol 36, 1236–1243.
146. TeKippe M, Harrison DE & Chen J (2003) Expansion of hematopoietic stem cell phenotype and activity in Trp53-null mice. Exp Hematol 31, 521–527.
147. Wlodarski P, Wasik M, Ratajczak MZ, Sevignani C, Hoser G, Kawiak J, Gewirtz AM, Calabretta B & Skorski T (1998) Role of p53 in hematopoietic recovery after cytotoxic treatment. Blood 91, 2998–3006.
148. Marusyk A, Porter CC, Zaberezhnyy V & DeGregori J (2010) Irradiation selects for p53-deficient hematopoietic progenitors. PLoS Biol 8, e1000324.
149. Bondar T & Medzhitov R (2010) p53-mediated hematopoietic stem and progenitor cell competition. Cell Stem Cell 6, 309–322.
150. Li W & Baker NE (2007) Engulfment is required for cell competition. Cell 129, 1215–1225.
151. Meyer SN, Amoyel M, Bergantinos C, de la Cova C, Schertel C, Basler K & Johnston LA (2014) An ancient defense system eliminates unfit cells from developing tissues during cell competition. Science (New York, NY) 346, 1258236.
152. Erlacher M & Strahm B (2015) Missing cells: pathophysiology, diagnosis, and management of (Pan)cytopenia in childhood. Front Pediat 3, 64.
153. Walter D, Lier A, Geiselhart A, Thalheimer FB, Huntscha S, Sobotta MC, Moehrle B, Brocks D, Bayindir I, Kaschutnig P et al. (2015) Exit from dormancy provokes DNA-damage-induced attrition in haematopoietic stem cells. Nature 520, 549–552.
154. Tsujimoto Y, Finger LR, Yunis J, Nowell PC & Croce CM (1984) Cloning of the chromosome breakpoint of neoplastic B cells with the t(14;18) chromosome translocation. Science (New York, NY) 226, 1097–1099.
155. McDonnell TJ, Deane N, Platt FM, Nunez G, Jaeger U, McKearn JP & Korsmeyer SJ (1989) bcl-2-immunoglobulin transgenic mice demonstrate extended B cell survival and follicular lymphoproliferation. Cell 57, 79–88.
156. Strasser A, Whittingham S, Vaux DL, Bath ML, Adams JM, Cory S & Harris AW (1991) Enforced BCL2 expression in B-lymphoid cells prolongs antibody responses and elicits autoimmune disease. Proc Natl Acad Sci USA 88, 8661–8665.
157. Demirer T, Buckner CD & Bensinger WI (1996) Optimization of peripheral blood stem cell mobilization. Stem Cells (Dayton, Ohio) 14, 106–116.
158. Rocha V & Broxmeyer HE (2010) New approaches for improving engraftment after cord blood transplantation. Biol Blood Marrow Transplant 16, S126–S132.
159. Mantel CR, O'Leary HA, Chitteti BR, Huang X, Cooper S, Hangoc G, Brustovetsky N, Srour EF, Lee MR, Messina-Graham S et al. (2015) Enhancing hematopoietic stem cell transplantation efficacy by mitigating oxygen shock. Cell 161, 1553–1565.
160. Hu L, Cheng H, Gao Y, Shi M, Liu Y, Hu Z, Xu J, Qiu L, Yuan W, Leung AY et al. (2014) Antioxidant N-acetyl-l-cysteine increases engraftment of human hematopoietic stem cells in immune-deficient mice. Blood 124, e45–e48.
161. Delbridge AR & Strasser A (2015) The BCL-2 protein family, BH3-mimetics and cancer therapy. Cell Death Differ 22, 1071–1080.
162. Tse C, Shoemaker AR, Adickes J, Anderson MG, Chen J, Jin S, Johnson EF, Marsh KC, Mitten MJ, Nimmer P et al. (2008) ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res 68, 3421–3428.
163. Zhang H, Nimmer PM, Tahir SK, Chen J, Fryer RM, Hahn KR, Iciek LA, Morgan SJ, Nasarre MC, Nelson R et al. (2007) Bcl-2 family proteins are essential for platelet survival. Cell Death Differ 14, 943–951.
164. Goessling W, Allen RS, Guan X, Jin P, Uchida N, Dovey M, Harris JM, Metzger ME, Bonifacino AC, Stroncek D et al. (2011) Prostaglandin E2 enhances human cord blood stem cell xenotransplants and shows long-term safety in preclinical nonhuman primate transplant models. Cell Stem Cell 8, 445–458.
165. Doan PL, Himburg HA, Helms K, Russell JL, Fixsen E, Quarmyne M, Harris JR, Deoliviera D, Sullivan JM, Chao NJ et al. (2013) Epidermal growth factor regulates hematopoietic regeneration after radiation injury. Nat Med 19, 295–304.
166. Dygai AM, Khmelevskaya ES, Skurikhin EG, Pershina OV, Andreeva TV & Ermakova NN (2012) Catecholamine regulation of stromal precursors and hemopoietic stem cells in cytostatic myelosuppression. Bull Exp Biol Med 152, 723–727.
167. Suda T, Takubo K & Semenza GL (2011) Metabolic regulation of hematopoietic stem cells in the hypoxic niche. Cell Stem Cell 9, 298–310.
168. Pestina TI, Cleveland JL, Yang C, Zambetti GP & Jackson CW (2001) Mpl ligand prevents lethal myelosuppression by inhibiting p53-dependent apoptosis. Blood 98, 2084–2090.
169. Bartucci M, Dattilo R, Martinetti D, Todaro M, Zapparelli G, Di Virgilio A, Biffoni M, De Maria R & Zeuner A (2011) Prevention of chemotherapy-induced anemia and thrombocytopenia by constant administration of stem cell factor. Clin Cancer Res 17, 6185–6191.
170. Porter RL, Georger MA, Bromberg O, McGrath KE, Frisch BJ, Becker MW & Calvi LM (2013) Prostaglandin E2 increases hematopoietic stem cell survival and accelerates hematopoietic recovery after radiation injury. Stem Cells (Dayton, Ohio) 31, 372–383.
171. Villunger A, Scott C, Bouillet P & Strasser A (2003) Essential role for the BH3-only protein Bim but redundant roles for Bax, Bcl-2, and Bcl-w in the control of granulocyte survival. Blood 101, 2393–2400.
172. Andina N, Conus S, Schneider EM, Fey MF & Simon HU (2009) Induction of Bim limits cytokine-mediated prolonged survival of neutrophils. Cell Death Differ 16, 1248–1255.
173. Zinkel SS, Ong CC, Ferguson DO, Iwasaki H, Akashi K, Bronson RT, Kutok JL, Alt FW & Korsmeyer SJ (2003) Proapoptotic BID is required for myeloid homeostasis and tumor suppression. Genes Dev 17, 229–239.
174. Ekoff M, Kaufmann T, Engstrom M, Motoyama N, Villunger A, Jonsson JI, Strasser A & Nilsson G (2007) The BH3-only protein Puma plays an essential role in cytokine deprivation induced apoptosis of mast cells. Blood 110, 3209–3217.
175. Baumgartner F, Woess C, Pedit V, Tzankov A, Labi V & Villunger A (2013) Minor cell-death defects but reduced tumor latency in mice lacking the BH3-only proteins Bad and Bmf. Oncogene 32, 621–630.
176. Kelly PN, White MJ, Goschnick MW, Fairfax KA, Tarlinton DM, Kinkel SA, Bouillet P, Adams JM, Kile BT & Strasser A (2010) Individual and overlapping roles of BH3-only proteins Bim and Bad in apoptosis of lymphocytes and platelets and in suppression of thymic lymphoma development. Cell Death Differ 17, 1655–1664.
177. Imaizumi K, Benito A, Kiryu-Seo S, Gonzalez V, Inohara N, Lieberman AP, Kiyama H & Nunez G (2004) Critical role for DP5/Harakiri, a Bcl-2 homology domain 3-only Bcl-2 family member, in axotomy-induced neuronal cell death. J Neurosci 24, 3721–3725.
178. Coultas L, Terzano S, Thomas T, Voss A, Reid K, Stanley EG, Scott CL, Bouillet P, Bartlett P, Ham J et al. (2007) Hrk/DP5 contributes to the apoptosis of select neuronal populations but is dispensable for haematopoietic cell apoptosis. J Cell Sci 120, 2044–2052.
179. Coultas L, Bouillet P, Stanley EG, Brodnicki TC, Adams JM & Strasser A (2004) Proapoptotic BH3-only Bcl-2 family member Bik/Blk/Nbk is expressed in hemopoietic and endothelial cells but is redundant for their programmed death. Mol Cell Biol 24, 1570–1581.
180. Masson F, Kupresanin F, Mount A, Strasser A & Belz GT (2011) Bid and Bim collaborate during induction of T cell death in persistent infection. J Immunol (Baltimore, Md.: 1950) 186, 4059–4066.
181. Bauer A, Villunger A, Labi V, Fischer SF, Strasser A, Wagner H, Schmid RM & Hacker G (2006) The NF-kappaB regulator Bcl-3 and the BH3-only proteins Bim and Puma control the death of activated T cells. Proc Natl Acad Sci USA 103, 10979–10984.
182. Coultas L, Bouillet P, Loveland KL, Meachem S, Perlman H, Adams JM & Strasser A (2005) Concomitant loss of proapoptotic BH3-only Bcl-2 antagonists Bik and Bim arrests spermatogenesis. EMBO J 24, 3963–3973.
183. Michalak EM, Villunger A, Adams JM & Strasser A (2008) In several cell types tumour suppressor p53 induces apoptosis largely via Puma but Noxa can contribute. Cell Death Differ 15, 1019–1029.
184. Ren D, Tu HC, Kim H, Wang GX, Bean GR, Takeuchi O, Jeffers JR, Zambetti GP, Hsieh JJ & Cheng EH (2010) BID, BIM, and PUMA are essential for activation of the BAX- and BAK-dependent cell death program. Science (New York, NY) 330, 1390–1393.
185. Knudson CM, Tung KS, Tourtellotte WG, Brown GA & Korsmeyer SJ (1995) Bax-deficient mice with lymphoid hyperplasia and male germ cell death. Science (New York, NY) 270, 96–99.
186. Lindsten T, Ross AJ, King A, Zong WX, Rathmell JC, Shiels HA, Ulrich E, Waymire KG, Mahar P, Frauwirth K et al. (2000) The combined functions of proapoptotic Bcl-2 family members bak and bax are essential for normal development of multiple tissues. Mol Cell 6, 1389–1399.
187. Ke F, Voss A, Kerr JB, O'Reilly LA, Tai L, Echeverry N, Bouillet P, Strasser A & Kaufmann T (2012) BCL-2 family member BOK is widely expressed but its loss has only minimal impact in mice. Cell Death Differ 19, 915–925.
188. Ke F, Grabow S, Kelly G, Lin A, O'Reilly L & Strasser A (2015) Impact of the combined loss of BOK, BAX and BAK on the hematopoietic system is slightly more severe than compound loss of BAX and BAK. Cell Death Dis 6, e1938.
189. Pereboom TC, van Weele LJ, Bondt A & MacInnes AW (2011) A zebrafish model of dyskeratosis congenita reveals hematopoietic stem cell formation failure resulting from ribosomal protein-mediated p53 stabilization. Blood 118, 5458–5465.
190. Sperka T, Song Z, Morita Y, Nalapareddy K, Guachalla LM, Lechel A, Begus-Nahrmann Y, Burkhalter MD, Mach M, Schlaudraff F et al. (2012) Puma and p21 represent cooperating checkpoints limiting self-renewal and chromosomal instability of somatic stem cells in response to telomere dysfunction. Nat Cell Biol 14, 73–79.
191. Zhang Y, Morimoto K, Danilova N, Zhang B & Lin S (2012) Zebrafish models for dyskeratosis congenita reveal critical roles of p53 activation contributing to hematopoietic defects through RNA processing. PLoS One 7, e30188.
192. Baruque GA, Bitencourt MA, Pasquini R, Castelo-Branco MT, Llerena JC Jr & Rumjanek VM (2005) Apoptosis and expression of anti- and pro-apoptotic proteins in peripheral blood mononuclear cells of Fanconi anaemia patients: a study of 73 cases. Eur J Haematol 75, 384–390.
193. Prieto-Remon I, Sanchez-Carrera D, Lopez-Duarte M, Richard C & Pipaon C (2012) BIK (NBK) is a mediator of the sensitivity of Fanconi anaemia group C lymphoblastoid cell lines to interstrand DNA cross-linking agents. Biochem J 448, 153–163.
194. Ceccaldi R, Parmar K, Mouly E, Delord M, Kim JM, Regairaz M, Pla M, Vasquez N, Zhang QS, Pondarre C et al. (2012) Bone marrow failure in Fanconi anemia is triggered by an exacerbated p53/p21 DNA damage response that impairs hematopoietic stem and progenitor cells. Cell Stem Cell 11, 36–49.
195. Kirito K, Watanabe T, Sawada K, Endo H, Ozawa K & Komatsu N (2002) Thrombopoietin regulates Bcl-xL gene expression through Stat5 and phosphatidylinositol 3-kinase activation pathways. J Biol Chem 277, 8329–8337.
196. Sigurjonsson OE, Gudmundsson KO, Haraldsdottir V, Rafnar T, Agnarsson BA & Gudmundsson S (2004) Flt3/Flk-2 ligand in combination with thrombopoietin decreases apoptosis in megakaryocyte development. Stem Cells Dev 13, 183–191.
197. Lannutti BJ, Epp A, Roy J, Chen J & Josephson NC (2009) Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis. Blood 113, 1778–1785.
198. Letestu R, Vitrat N, Masse A, Le Couedic JP, Lazar V, Rameau P, Wendling F, Vuillier J, Boutard P, Plouvier E et al. (2000) Existence of a differentiation blockage at the stage of a megakaryocyte precursor in the thrombocytopenia and absent radii (TAR) syndrome. Blood 95, 1633–1641.
199. Klein C (2011) Genetic defects in severe congenital neutropenia: emerging insights into life and death of human neutrophil granulocytes. Annu Rev Immunol 29, 399–413.
200. Gautam S, Kirschnek S, Gentle IE, Kopiniok C, Henneke P, Hacker H, Malleret L, Belaaouaj A & Hacker G (2013) Survival and differentiation defects contribute to neutropenia in glucose-6-phosphatase-beta (G6PC3) deficiency in a model of mouse neutrophil granulocyte differentiation. Cell Death Differ 20, 1068–1079.
201. Watanabe K, Ambekar C, Wang H, Ciccolini A, Schimmer AD & Dror Y (2009) SBDS-deficiency results in specific hypersensitivity to Fas stimulation and accumulation of Fas at the plasma membrane. Apoptosis 14, 77–89.
202. Zambetti NA, Bindels EM, Van Strien PM, Valkhof MG, Adisty MN, Hoogenboezem RM, Sanders MA, Rommens JM, Touw IP & Raaijmakers MH (2015) Deficiency of the ribosome biogenesis gene Sbds in hematopoietic stem and progenitor cells causes neutropenia in mice by attenuating lineage progression in myelocytes. Haematologica 100, 1285–1293.
203. Danilova N, Sakamoto KM & Lin S (2008) Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 112, 5228–5237.
204. Jaako P, Flygare J, Olsson K, Quere R, Ehinger M, Henson A, Ellis S, Schambach A, Baum C, Richter J et al. (2011) Mice with ribosomal protein S19 deficiency develop bone marrow failure and symptoms like patients with Diamond-Blackfan anemia. Blood 118, 6087–6096.
205. Zhang Y, Ear J, Yang Z, Morimoto K, Zhang B & Lin S (2014) Defects of protein production in erythroid cells revealed in a zebrafish Diamond-Blackfan anemia model for mutation in RPS19. Cell Death Dis 5, e1352.
206. Castaneda S, Boosalis MS, Emery D, Thies A, Faller DV & Perrine SP (2005) Enhancement of growth and survival and alterations in Bcl-family proteins in beta-thalassemic erythroid progenitors by novel short-chain fatty acid derivatives. Blood Cells Mol Dis 35, 217–226.
207. Maraskovsky E, O'Reilly LA, Teepe M, Corcoran LM, Peschon JJ & Strasser A (1997) Bcl-2 can rescue T lymphocyte development in interleukin-7 receptor-deficient mice but not in mutant rag-1-/- mice. Cell 89, 1011–1019.
208. Rodewald HR, Waskow C & Haller C (2001) Essential requirement for c-kit and common gamma chain in thymocyte development cannot be overruled by enforced expression of Bcl-2. J Exp Med 193, 1431–1437.
209. Rissone A, Weinacht KG, la Marca G, Bishop K, Giocaliere E, Jagadeesh J, Felgentreff K, Dobbs K, Al-Herz W, Jones M et al. (2015) Reticular dysgenesis-associated AK2 protects hematopoietic stem and progenitor cell development from oxidative stress. J Exp Med 212, 1185–1202.
210. Six E, Lagresle-Peyrou C, Susini S, De Chappedelaine C, Sigrist N, Sadek H, Chouteau M, Cagnard N, Fontenay M, Hermine O et al. (2015) AK2 deficiency compromises the mitochondrial energy metabolism required for differentiation of human neutrophil and lymphoid lineages. Cell Death Dis 6, e1856.
211. Koury MJ & Ponka P (2004) New insights into erythropoiesis: the roles of folate, vitamin B12, and iron. Annu Rev Nutr 24, 105–131.
212. Koury MJ, Price JO & Hicks GG (2000) Apoptosis in megaloblastic anemia occurs during DNA synthesis by a p53-independent, nucleoside-reversible mechanism. Blood 96, 3249–3255.
213. Moffatt S, Yaegashi N, Tada K, Tanaka N & Sugamura K (1998) Human parvovirus B19 nonstructural (NS1) protein induces apoptosis in erythroid lineage cells. J Virol 72, 3018–3028.
214. Kurotaki H, Tsushima Y, Nagai K & Yagihashi S (2000) Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia. Acta Haematol 102, 115–123.
215. Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S & Pagliuca A (2000) The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS. Blood 96, 3932–3938.
216. Boudard D, Vasselon C, Bertheas MF, Jaubert J, Mounier C, Reynaud J, Viallet A, Chautard S, Guyotat D & Campos L (2002) Expression and prognostic significance of Bcl-2 family proteins in myelodysplastic syndromes. Am J Hematol 70, 115–125.
217. Callera F, Garcia AB & Falcao RP (1998) Fas-mediated apoptosis with normal expression of bcl-2 and p53 in lymphocytes from aplastic anaemia. Br J Haematol 100, 698–703.
218. Ismail M, Gibson FM, Gordon-Smith EC & Rutherford TR (2001) Bcl-2 and Bcl-x expression in the CD34+ cells of aplastic anaemia patients: relationship with increased apoptosis and upregulation of Fas antigen. Br J Haematol 113, 706–712.
219. Sloand E, Kim S, Maciejewski JP, Tisdale J, Follmann D & Young NS (2002) Intracellular interferon-gamma in circulating and marrow T cells detected by flow cytometry and the response to immunosuppressive therapy in patients with aplastic anemia. Blood 100, 1185–1191.
220. Scheid MP, Schubert KM & Duronio V (1999) Regulation of bad phosphorylation and association with Bcl-x(L) by the MAPK/Erk kinase. J Biol Chem 274, 31108–31113.
221. Ley R, Balmanno K, Hadfield K, Weston C & Cook SJ (2003) Activation of the ERK1/2 signaling pathway promotes phosphorylation and proteasome-dependent degradation of the BH3-only protein, Bim. J Biol Chem 278, 18811–18816.
222. Chan G, Cheung LS, Yang W, Milyavsky M, Sanders AD, Gu S, Hong WX, Liu AX, Wang X, Barbara M et al. (2011) Essential role for Ptpn11 in survival of hematopoietic stem and progenitor cells. Blood 117, 4253–4261.
223. Timeus F, Crescenzio N, Baldassarre G, Doria A, Vallero S, Foglia L, Pagliano S, Rossi C, Silengo MC, Ramenghi U et al. (2013) Functional evaluation of circulating hematopoietic progenitors in Noonan syndrome. Oncol Rep 30, 553–559.
224. Isaian A, Bogdanova NV, Houshmand M, Movahadi M, Aghamohammadi A, Rezaei N, Atarod L, Sadeghi-Shabestari M, Tonekaboni SH, Chavoshzadeh Z et al. (2010) BAK, BAX, and NBK/BIK proapoptotic gene alterations in Iranian patients with ataxia telangiectasia. J Clin Immunol 30, 132–137.
225. Kabacik S, Ortega-Molina A, Efeyan A, Finnon P, Bouffler S, Serrano M & Badie C (2011) A minimally invasive assay for individual assessment of the ATM/CHEK2/p53 pathway activity. Cell Cycle (Georgetown, Tex) 10, 1152–1161.
226. Jongmans W, Vuillaume M, Chrzanowska K, Smeets D, Sperling K & Hall J (1997) Nijmegen breakage syndrome cells fail to induce the p53-mediated DNA damage response following exposure to ionizing radiation. Mol Cell Biol 17, 5016–5022.
227. Zhang Y, Lim CU, Zhou J & Liber HH (2007) The effects of NBS1 knockdown by small interfering RNA on the ionizing radiation-induced apoptosis in human lymphoblastoid cells with different p53 status. Toxicol Lett 171, 50–59.
228. Li H, Zhu H, Xu CJ & Yuan J (1998) Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94, 491–501.
229. Niss O, Sholl A, Bleesing JJ & Hildeman DA (2015) IL-10/Janus kinase/signal transducer and activator of transcription 3 signaling dysregulates Bim expression in autoimmune lymphoproliferative syndrome. J Allergy Clin Immunol 135, 762–770.
230. Oliveira JB, Bidere N, Niemela JE, Zheng L, Sakai K, Nix CP, Danner RL, Barb J, Munson PJ, Puck JM et al. (2007) NRAS mutation causes a human autoimmune lymphoproliferative syndrome. Proc Natl Acad Sci USA 104, 8953–8958.
231. Niemela JE, Lu L, Fleisher TA, Davis J, Caminha I, Natter M, Beer LA, Dowdell KC, Pittaluga S, Raffeld M et al. (2011) Somatic KRAS mutations associated with a human nonmalignant syndrome of autoimmunity and abnormal leukocyte homeostasis. Blood 117, 2883–2886.
232. Yoshioka K, Yamamoto S, Moriguchi N, Miyata H, Tsukiyama K, Isokawa S, Horiuchi F & Takemura T (2000) Overexpression of bcl-2 in transient abnormal myelopoiesis associated with Down syndrome. Ann Hematol 79, 319–321.
233. Marshall GM, Carter DR, Cheung BB, Liu T, Mateos MK, Meyerowitz JG & Weiss WA (2014) The prenatal origins of cancer. Nat Rev Cancer 14, 277–289.
234. Silva M, Richard C, Benito A, Sanz C, Olalla I & Fernandez-Luna JL (1998) Expression of Bcl-x in erythroid precursors from patients with polycythemia vera. New Engl J Med 338, 564–571.
235. Zeuner A, Pedini F, Francescangeli F, Signore M, Girelli G, Tafuri A & De Maria R (2009) Activity of the BH3 mimetic ABT-737 on polycythemia vera erythroid precursor cells. Blood 113, 1522–1525.
236. Will B, Siddiqi T, Jorda MA, Shimamura T, Luptakova K, Staber PB, Costa DB, Steidl U, Tenen DG & Kobayashi S (2010) Apoptosis induced by JAK2 inhibition is mediated by Bim and enhanced by the BH3 mimetic ABT-737 in JAK2 mutant human erythroid cells. Blood 115, 2901–2909.
237. Rubert J, Qian Z, Andraos R, Guthy DA & Radimerski T (2011) Bim and Mcl-1 exert key roles in regulating JAK2V617F cell survival. BMC Cancer 11, 24.
238. Tognon R, Gasparotto EP, Neves RP, Nunes NS, Ferreira AF, Palma PV, Kashima S, Covas DT, Santana M, Souto EX et al. (2012) Deregulation of apoptosis-related genes is associated with PRV1 overexpression and JAK2 V617F allele burden in essential thrombocythemia and myelofibrosis. J Hematol Oncol 5, 2.
239. Kuroda J, Puthalakath H, Cragg MS, Kelly PN, Bouillet P, Huang DC, Kimura S, Ottmann OG, Druker BJ, Villunger A et al. (2006) Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimetic. Proc Natl Acad Sci USA 103, 14907–14912.
240. Ng KP, Hillmer AM, Chuah CT, Juan WC, Ko TK, Teo AS, Ariyaratne PN, Takahashi N, Sawada K, Fei Y et al. (2012) A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med 18, 521–528.
241. Aichberger KJ, Mayerhofer M, Krauth MT, Vales A, Kondo R, Derdak S, Pickl WF, Selzer E, Deininger M, Druker BJ et al. (2005) Low-level expression of proapoptotic Bcl-2-interacting mediator in leukemic cells in patients with chronic myeloid leukemia: role of BCR/ABL, characterization of underlying signaling pathways, and reexpression by novel pharmacologic compounds. Cancer Res 65, 9436–9444.
242. Jilg S, Reidel V, Muller-Thomas C, Konig J, Schauwecker J, Hockendorf U, Huberle C, Gorka O, Schmidt B, Burgkart R et al. (2016) Blockade of BCL-2 proteins efficiently induces apoptosis in progenitor cells of high-risk myelodysplastic syndromes patients. Leukemia 30, 112–123.
243. Yoshimoto G, Miyamoto T, Jabbarzadeh-Tabrizi S, Iino T, Rocnik JL, Kikushige Y, Mori Y, Shima T, Iwasaki H, Takenaka K et al. (2009) FLT3-ITD up-regulates MCL-1 to promote survival of stem cells in acute myeloid leukemia via FLT3-ITD-specific STAT5 activation. Blood 114, 5034–5043.
244. Wang R, Xia L, Gabrilove J, Waxman S & Jing Y (2016) Sorafenib inhibition of Mcl-1 accelerates ATRA-induced apoptosis in differentiation-responsive AML cells. Clin Cancer Res 22, 1211–1221.
245. Chan SM, Thomas D, Corces-Zimmerman MR, Xavy S, Rastogi S, Hong WJ, Zhao F, Medeiros BC, Tyvoll DA & Majeti R (2015) Isocitrate dehydrogenase 1 and 2 mutations induce BCL-2 dependence in acute myeloid leukemia. Nat Med 21, 178–184.
246. Yang Z, Li Y, Yin F & Chan RJ (2008) Activating PTPN11 mutants promote hematopoietic progenitor cell-cycle progression and survival. Exp Hematol 36, 1285–1296.
247. Ploner C, Rainer J, Niederegger H, Eduardoff M, Villunger A, Geley S & Kofler R (2008) The BCL2 rheostat in glucocorticoid-induced apoptosis of acute lymphoblastic leukemia. Leukemia 22, 370–377.
248. Jiang N, Koh GS, Lim JY, Kham SK, Ariffin H, Chew FT & Yeoh AE (2011) BIM is a prognostic biomarker for early prednisolone response in pediatric acute lymphoblastic leukemia. Exp Hematol 39, 321–329, 329.e1–3.
249. Queudeville M, Seyfried F, Eckhoff SM, Trentin L, Ulrich S, Schirmer M, Debatin KM & Meyer LH (2012) Rapid engraftment of human ALL in NOD/SCID mice involves deficient apoptosis signaling. Cell Death Dis 3, e364.
250. Fischer U, Forster M, Rinaldi A, Risch T, Sungalee S, Warnatz H-J, Bornhauser B, Gombert M, Kratsch C & Stütz AM (2015) Genomics and drug profiling of fatal TCF3-HLF-positive acute lymphoblastic leukemia identifies recurrent mutation patterns and therapeutic options. Nat Genet 47, 1020–1029.
251. Vogler M, Butterworth M, Majid A, Walewska RJ, Sun XM, Dyer MJ & Cohen GM (2009) Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia. Blood 113, 4403–4413.
252. Del Gaizo Moore V, Brown JR, Certo M, Love TM, Novina CD & Letai A (2007) Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. J Clin Investig 117, 112–121.
253. Hamilton E, Pearce L, Morgan L, Robinson S, Ware V, Brennan P, Thomas NS, Yallop D, Devereux S, Fegan C et al. (2012) Mimicking the tumour microenvironment: three different co-culture systems induce a similar phenotype but distinct proliferative signals in primary chronic lymphocytic leukaemia cells. Br J Haematol 158, 589–599.
254. Kridel R, Sehn LH & Gascoyne RD (2012) Pathogenesis of follicular lymphoma. J Clin Investig 122, 3424–3431.
255. Correia C, Schneider PA, Dai H, Dogan A, Maurer MJ, Church AK, Novak AJ, Feldman AL, Wu X, Ding H et al. (2015) BCL2 mutations are associated with increased risk of transformation and shortened survival in follicular lymphoma. Blood 125, 658–667.
256. Roulland S, Kelly RS, Morgado E, Sungalee S, Solal-Celigny P, Colombat P, Jouve N, Palli D, Pala V, Tumino R et al. (2014) t(14;18) Translocation: a predictive blood biomarker for follicular lymphoma. J Clin Oncol 32, 1347–1355.
257. Kelly PN, Grabow S, Delbridge AR, Strasser A & Adams JM (2011) Endogenous Bcl-xL is essential for Myc-driven lymphomagenesis in mice. Blood 118, 6380–6386.
258. Michalak EM, Jansen ES, Happo L, Cragg MS, Tai L, Smyth GK, Strasser A, Adams JM & Scott CL (2009) Puma and to a lesser extent Noxa are suppressors of Myc-induced lymphomagenesis. Cell Death Differ 16, 684–696.
259. Egle A, Harris AW, Bouillet P & Cory S (2004) Bim is a suppressor of Myc-induced mouse B cell leukemia. Proc Natl Acad Sci USA 101, 6164–6169.
260. Frenzel A, Labi V, Chmelewskij W, Ploner C, Geley S, Fiegl H, Tzankov A & Villunger A (2010) Suppression of B-cell lymphomagenesis by the BH3-only proteins Bmf and Bad. Blood 115, 995–1005.